Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2019
Price : $35 *
At a glance
- Drugs Trabectedin (Primary)
- Indications Meningioma
- Focus Therapeutic Use
- 04 Jun 2019 Primary endpoint (Progression Free Survival (PFS)) has not been met, according to the results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2019 Efficacy results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 16 May 2019 According to a PharmaMar media release, data will be presented at the American Society of Clinical Oncology 2019 (ASCO).